Tadalafil NDC 70518-4605

NDC codes

FDA NDC Directory

Product NDC (as listed)70518-4605Labeler and product segments. Claims need a package NDC.

Product NDC at billing width70518-4605Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
70518-4605-0	70518460500	50 POUCH in 1 BOX (70518-4605-0) / 1 TABLET in 1 POUCH (70518-4605-1)Marketed from Apr 22, 2026

How the 11-digit form is made: The package segment has 1 digit, so one leading zero is added to it (5-4-1 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Tadalafil
Generic name (nonproprietary): tadalafil
Active ingredients: Tadalafil — 5 mg/1
Dosage form: Tablet
Route: Oral
Labeler: REMEDYREPACK INC.
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 211839
Marketing start: Apr 22, 2026
Listing expires: Dec 31, 2027
Other FDA classes: Phosphodiesterase 5 Inhibitors (Mechanism)
Identifiers: Product ID 70518-4605_50200848-abf9-c824-e063-6294a90a8190SPL ID 50200848-abf9-c824-e063-6294a90a8190SPL set ID 82dfea4c-9fe5-438a-917f-8f7d395ee8caRxCUI 403957UNII 742SXX0ICT
Pharmacologic class: Phosphodiesterase 5 Inhibitor

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N470518460500 followed by a unit qualifier and the quantity

Package 70518-4605-00. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Apr 23, 2026.

Indications (excerpt from the label)

Tadalafil tablets are a phosphodiesterase 5 (PDE5) inhibitor indicated for the treatment of: erectile dysfunction (ED) ( 1.1 ) the signs and symptoms of benign prostatic hyperplasia (BPH) ( 1.2 ) ED and the signs and symptoms of BPH (ED/BPH) ( 1.3 ) If tadalafil tablets are used with finasteride to initiate BPH treatment, such use is recommended for up to 26 weeks ( 1.4 ). 1.1 Erectile Dysfunction Tadalafil tablets are indicated for the treatment of erectile dysfunction (ED). 1.2 Benign Prostatic Hyperplasia Tadalafil tablets are indicated for the treatment of the signs and symptoms of benign prostatic hyperplasia (BPH). 1.3 Erectile Dysfunction and Benign Prostatic Hyperplasia Tadalafil tab…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 211839

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 211839
Product	Strength	Form · route	Labeler	Product NDC
Tadalafil	Tadalafil 5 mg/1	TabletOral	Preferred Pharmaceuticals Inc.	68788-4018
Tadalafil	Tadalafil 2.5 mg/1	TabletOral	Torrent Pharmaceuticals Limited	13668-565
Tadalafil	Tadalafil 5 mg/1	TabletOral	Torrent Pharmaceuticals Limited	13668-566
Tadalafil	Tadalafil 10 mg/1	TabletOral	Torrent Pharmaceuticals Limited	13668-567
Tadalafil	Tadalafil 20 mg/1	TabletOral	Torrent Pharmaceuticals Limited	13668-568
Tadalafil	Tadalafil 5 mg/1	TabletOral	Asclemed USA, Inc.	76420-546